The global osteoporosis market has been forecast to increase from a valuation of approximately $7.3 billion in 2010, to hit a market value of $11.4 billion by 2015.
Over the next decade, growth in elderly population across the world, and the resultant increase in potential osteoporosis patients, is poised to offer several opportunities for pharmaceutical companies in the osteoporosis market.
However, growth in the number of patients is not expected to lead to growth in the overall value of the global osteoporosis market. This is due to the genericization of key bisphosphonate brands, which will cause price erosion, and lead to the industry actually witnessing a decline in growth between 2013 and 2021.
Osteoporosis represents an implacable epidemic growing rapidly in regions of North America, Europe, and Japan.
As per International Osteoporosis Foundation census, more than 200 million people in the world are affected by osteoporosis, of which about 80% are women.
Currently, the global osteoporosis drugs market is dominated by the bisphosphonate class, with Roche's Bonviva/Boniva (ibandronic acid) and Novartis' Aclasta/Zometa (zoledronate) accounting for healthy market shares and showing an average sales growth rate of about 20% in the past two years.
Amgen's Prolia (denosumab) is the most recent entrant to the osteoporosis treatment market, following approval from the US Food and Drug Administration (FDA) and the European Commission, and is expected to compete directly with the bisphosphonate products, although its initial uptake is likely to be in second-line therapy, mostly in patients who are intolerant to these treatments.
For more information on the global osteoporosis market, see the latest research: Global Osteoporosis Market
Follow us on Twitter @CandMResearch
Companiesandmarkets.com issues news updates and report summaries covering all major industries and sectors. The service provides additional client monitoring and timely alerts to breaking industry and sector news leading the day's business headlines. News articles, written by our staff, contain additional analyst insight, providing value added insight for our readers. News updates and real-time alerts on newly-released market reports are also available from our Facebook page, Twitter feed @CandMResearch and RSS links. We also welcome inquiries from business journalists and the news media.